What 'Peptide Therapy' Actually Means
The phrase covers everything from rigorously tested prescription drugs to compounds never completed in a single human trial. Here is how to tell them apart.
Walk into a wellness clinic, scroll a fitness forum, or open a targeted ad, and you will keep meeting the same phrase: peptide therapy. It sounds like one thing. It is not. "Peptide" simply means a short chain of amino acids, the same building blocks that make up proteins. Dozens of very different substances get sold under the peptide-therapy banner, and they range from rigorously tested prescription medicines to compounds that have never been tested in a single completed human trial. The most important thing to understand is that evidence and legal standing do not carry over from one to the next.
Think of a spectrum. At one end sit FDA-approved peptide drugs, made under regulated manufacturing and studied in large trials. In the middle sit compounded copies of those same drugs. At the far end sit "research" or "wellness" peptides with names like BPC-157 and TB-500. Below, we walk from one end to the other.
The approved end: real drugs, real trial data
The peptides with the strongest evidence are the GLP-1 medicines you have probably heard about. In the SELECT trial, 17,604 adults who had obesity and established cardiovascular disease but not diabetes took either once-weekly semaglutide 2.4 mg (Wegovy) or a placebo and were followed for a mean of about 40 months. Major adverse cardiovascular events, meaning cardiovascular death, nonfatal heart attack, or nonfatal stroke, occurred in 6.5% of the semaglutide group versus 8.0% on placebo, a 20% relative reduction (hazard ratio 0.80). This is hard outcomes data: the drug did not just move a number on a chart, it reduced serious events.
Tirzepatide (Zepbound/Mounjaro), which acts on two receptors at once, produced large weight loss in the SURMOUNT-1 trial. Among 2,539 adults with obesity or overweight and without diabetes, average weight loss over 72 weeks was roughly 15.0% at the 5 mg dose, 19.5% at 10 mg, and 20.9% at 15 mg, compared with 3.1% on placebo. (Those are the trial's treatment-regimen-estimand figures, which count everyone regardless of whether they stayed on the drug; the efficacy-estimand numbers, which model full adherence, run slightly higher, around 16.0/21.4/22.5% versus 2.4% on placebo. Both come from the same study.)
Not every approved peptide is about metabolism. PT-141 (bremelanotide, brand Vyleesi) was cleared in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is an on-demand injection, and its benefit was statistically significant but modest: in the two Phase 3 RECONNECT trials, it improved the co-primary measures of sexual desire and desire-related distress (both p<0.001), but it did not significantly increase the number of satisfying sexual events versus placebo. Roughly 40% of users experienced nausea. It is approved only for that specific group, though it is marketed off-label and through grey-market channels to others.
Evidence and legal standing do not carry over from one peptide to the next, even when the molecule is the same.
The compounded middle: same molecule, different rules
During recent shortages, pharmacies were allowed to compound their own versions of these GLP-1 drugs. That legal window has largely closed. On February 21, 2025, the FDA declared the semaglutide shortage resolved (the tirzepatide shortage was resolved in late 2024). Once a drug leaves the shortage list, compounding is generally no longer permitted: 503A pharmacies had until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, to wind down semaglutide compounding.
The safety concern is that compounded and unapproved versions bypass FDA review for quality, safety, and effectiveness. Reported harms include dosing errors from self-drawn multidose vials, with some patients taking 10 to 20 times the intended dose, use of untested salt forms such as semaglutide sodium, and degradation of these fragile molecules from improper storage. The strong trial results apply to specific molecules, specific doses, and FDA-approved manufacturing; they do not automatically extend to a compounded copy.
One note on numbers you may encounter: figures like "about 95% of 2024 GLP-1 adverse events involved dosing" or "poison-control calls up more than 15-fold since 2019" come from secondary reporting and should be treated as indicative rather than definitive.
The far end: research and wellness peptides
At the other end of the spectrum are the peptides most heavily marketed by wellness clinics for healing, recovery, longevity, and more: BPC-157, TB-500 (thymosin beta-4), KPV, MOTS-c, Semax, Epitalon, and others. These are not FDA-approved, and they sit in a regulatory grey zone. In 2023 the FDA placed roughly a dozen such peptides in Category 2 of its 503A bulk-substances list, meaning they were judged to raise significant safety concerns and were unsafe for bulk compounding.
For the most-hyped of these, BPC-157, human evidence is essentially absent. A 2025 peer-reviewed literature and patent review concluded there are no completed clinical studies describing its efficacy in humans. The evidence base is almost entirely rodent studies. A 2015 Phase I safety trial in 42 healthy volunteers had its results withdrawn in 2016, never submitted. In plain terms, the marketed claims rest on animal and cell data, not on human trials.
What about "anti-aging" peptides and hormones?
A common selling point is that peptides can slow aging or restore youthful vigor. The broader logic behind that pitch is not supported by outcomes evidence. Growth hormone is the clearest cautionary example: a meta-analysis of randomized trials in healthy elderly people (Liu et al., Annals of Internal Medicine, 2007) found only small changes in body composition alongside increased adverse events, including joint pain, swelling, carpal tunnel syndrome, and insulin resistance. Growth hormone is FDA-approved for diagnosed deficiency and specific conditions, not for aging. That 2007 analysis is older and is cited here only to show that the anti-aging rationale lacks positive outcomes data, not as current treatment guidance.
The bottom line
"Peptide therapy" is a marketing umbrella, not a single regulated category. When you hear the term, the useful question is not "do peptides work?" but "which peptide, at what dose, for which population, made how, and studied how?" The answers differ enormously across the spectrum below.
- Approved GLP-1 peptides (semaglutide, tirzepatide)large trials show real benefits for weight and, for semaglutide in SELECT, cardiovascular events.
- Bremelanotide (PT-141)FDA-approved for one specific group, with a modest benefit on desire and distress and frequent nausea.
- Compounded copiessame active molecules, but they skip FDA review for quality, safety, and effectiveness, and carry documented dosing and quality risks; the legal window for compounding has largely closed.
- Research/wellness peptides (BPC-157, TB-500, and others)not approved, human evidence largely absent, regulatory status unsettled.
Strong data for one molecule says nothing about the safety or effectiveness of a compounded copy or an unrelated wellness peptide. If you are considering any of these, that distinction is the single most important thing to bring to a conversation with a licensed clinician.
- 01 RCT, 17,604 adults, mean follow-up ~40 months: semaglutide 2.4 mg cut major cardiovascular events 20% vs placebo (6.5% vs 8.0%, HR 0.80).
- 02 SURMOUNT-1 trial (Jastreboff et al.), N Engl J Med, 2022 pubmed.ncbi.nlm.nih.gov ↗RCT, 2,539 adults: tirzepatide 15.0/19.5/20.9% weight loss over 72 weeks vs 3.1% placebo (treatment-regimen estimand); efficacy-estimand figures ~16.0/21.4/22.5% vs 2.4%.
- 03 Bremelanotide RECONNECT Phase 3 trials (Kingsberg et al.), Obstet Gynecol, 2019; NIH LiverTox, 2019 pubmed.ncbi.nlm.nih.gov ↗PT-141/Vyleesi FDA-approved 2019 for acquired, generalized HSDD in premenopausal women; significant gains on desire and distress (p<0.001), no significant increase in satisfying sexual events; ~40% nausea.
- 04 FDA declared semaglutide shortage resolved Feb 21, 2025; 503A wind-down by Apr 22, 503B by May 22, 2025.
- 05 Stanford Medicine News, 2026 med.stanford.edu ↗Compounded GLP-1 risks: dosing errors (10-20x), untested salt forms, degradation; bypass of FDA review.
- 06 FDA Category 2 (2023) for research peptides; ~12 removed April 2026; PCAC review July 23-24, 2026, second meeting before end of Feb 2027.
- 07 Jozwiak et al., Pharmaceuticals (Basel), 2025 pmc.ncbi.nlm.nih.gov ↗BPC-157 review: no completed human efficacy studies; evidence almost entirely rodent; 2015 Phase I safety trial (42 volunteers) results withdrawn 2016.
- 08 Liu et al., systematic review, Annals of Internal Medicine, 2007 acpjournals.org ↗RCT meta-analysis in healthy elderly: small body-composition change, more adverse events; GH not recommended for anti-aging.
Wellness Wire Editorial
The Wellness Wire editorial team. Our explainers are researched from primary sources — clinical-trial reports and FDA labeling — and written for general education. They are not individually reviewed by a clinician and are not a substitute for medical advice.
